← Back to Screener
TuHURA Biosciences, Inc. Common Stock (HURA)
Price$2.24
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)26.66%
Price vs S&P 500 (4W)-7.98%
VGM Score52.50
Market Capitalization$143.92M
All Metrics
Book Value / Share (Quarterly)$0.36
P/TBV (Annual)4.76x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.43
Price vs S&P 500 (YTD)187.61%
EPS (TTM)$-0.61
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-0.61
EPS (Annual)$-0.63
Dividend / Share (Annual)$0.00
ROI (Annual)-142.23%
Cash / Share (Quarterly)$0.10
ROA (Last FY)-109.87%
EBITD / Share (TTM)$-0.62
ROE (5Y Avg)-542.49%
Cash Flow / Share (Annual)$-0.47
P/B Ratio6.21x
P/B Ratio (Quarterly)4.91x
Net Income / Employee (Annual)$-1,366,000
Net Interest Coverage (TTM)-4.30x
ROA (TTM)-105.38%
EPS Incl Extra (Annual)$-0.63
Current Ratio (Annual)0.78x
Quick Ratio (Quarterly)1.13x
3-Month Avg Trading Volume1.54M
52-Week Price Return-28.93%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.19
52-Week High$3.90
EPS Excl Extra (Annual)$-0.63
CapEx CAGR (5Y)50.06%
26-Week Price Return42.59%
Quick Ratio (Annual)0.78x
13-Week Price Return39.51%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)1.15x
Enterprise Value$137.62M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.06
3-Month Return Std Dev120.57%
Net Income / Employee (TTM)$-1,405,600
ROE (Last FY)-143.57%
Net Interest Coverage (Annual)-42.98x
EPS Basic Excl Extra (Annual)$-0.63
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.61
ROI (TTM)-151.82%
Dividend Growth Rate (5Y)-68.50%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.16
Price vs S&P 500 (52W)-57.14%
Year-to-Date Return198.55%
5-Day Price Return-9.60%
EPS Normalized (Annual)$-0.63
ROA (5Y Avg)-172.55%
Month-to-Date Return0.89%
EBITD / Share (Annual)$-0.67
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-542.23%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.61
P/TBV (Quarterly)9.55x
P/B Ratio (Annual)2.19x
Dividend / Share (TTM)$0.00
Book Value / Share (Annual)$0.35
Price vs S&P 500 (13W)29.76%
Dividend Yield (TTM)0.01%
Beta-0.00x
Revenue / Share (TTM)$0.00
ROE (TTM)-153.95%
52-Week Low$0.41
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.13est. -0.12
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HURATuHURA Biosciences, Inc. Common Stock | — | — | C | $2.24 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
TuHURA Biosciences is an immuno-oncology company advancing a personalized cancer vaccine candidate, IFx-2.0, designed to overcome primary resistance to checkpoint inhibitor immunotherapy. The company is preparing to initiate a Phase 3 registration trial evaluating IFx-2.0 in combination with Keytruda (pembrolizumab) as a first-line treatment for advanced or metastatic Merkel Cell Carcinoma.